Vir Biotechnology因计划出售股票而股价暴跌

路透中文
Nov 13
BUZZ-<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a>因计划出售股票而股价暴跌

11月12日 - ** Vir Biotechnology VIR.O 股价在盘后交易中暴跌15%,至10.30美元,因该公司寻求股权融资

** VIR 宣布发行 (link) 股票,但未披露交易规模

** 利瑞克(Leerink)、摩根士丹利(Morgan Stanley)和埃弗科(Evercore)担任联席簿记行

** 周一,VIR股价飙升近12%,收于13.64美元,此前该公司表示其慢性丁型肝炎 $(CHD)$ 疗法在III期临床试验中达到了主要终点 (link)

** 上月,该公司与吉利德(Gilead)GILD.O 签署了一项价值19亿美元的许可协议 (link),涉及三种针对特定实体瘤相关抗原的候选药物

** 根据招股说明书,该公司计划将本次发行所得净收益用于资助其CHD项目的商业化前活动、对其T细胞结合剂(TCE) 肿瘤治疗平台的投资,以及其他用途 (link)

** 总部位于加利福尼亚州旧金山的VIR公司流通股约为1.713亿股,市值约为21亿美元

** 该股周四收盘下跌7.7%,报12.12美元,但年初至今已翻倍

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10